Investors who have suffered losses can register their claims against the company on the Sina Investor Rights Protection Platform: http://wq.finance.sina.com.cn/ Follow @Sina Securities on Weibo, follow Sina Brokerage Fund on WeChat, search for Sina Investor Rights Protection on Baidu, access the Sina Finance app, or visit the Sina Finance homepage to find more information. Investor claims are currently being actively collected. Previously, the Haikou Intermediate People's Court has issued first-instance judgments in favor of investors suing Puli Pharmaceutical for securities misrepresentation liability disputes, ordering the company to compensate shareholders for their losses. Looking back at the case, on March 21, 2025, the company received a penalty decision from the China Securities Regulatory Commission (CSRC) for severe financial fraud that triggered a mandatory delisting due to major violations; the company officially exited the A-share market in April 2025. According to the judgment, investors who purchased shares between April 26, 2022, and April 16, 2024, and subsequently sold them after April 17, 2024, or continued to hold them and incurred losses are eligible to register for compensation. (Puli Pharmaceutical Rights Protection Portal) Attorney Liu Peng from Shanghai Huzi Law Firm, who is representing a batch of cases, has already received successful judgments. The statute of limitations for this case has not yet expired, and affected investors can check if their situation falls within the claimable period to participate in recovering their losses. (Attorney Liu Peng's Column) The financial report fraud has been severely punished. According to the announcement, the CSRC determined that the company inflated revenue and profits by fabricating sales of finished drugs and active pharmaceutical ingredients, and by accounting for trade business using the gross method. Calculations show that the company's falsely recorded operating revenue for 2021 and 2022 totaled 1.031 billion yuan, accounting for 31.08% of the total annual operating revenue disclosed for those two years; the falsely recorded total profit amounted to 695 million yuan, accounting for 76.72% of the total annual profit disclosed for the two-year period. The CSRC decided to order the company to make corrections, issue a warning, and impose a fine of 10 million yuan, with relevant responsible persons also receiving penalties. Investors who participate in the claim need to wait patiently. Although Puli Pharmaceutical's stock has been delisted, investors' rights to claim compensation are not affected. The CSRC has clearly stated that it will legally assist eligible investors who have suffered losses due to the listed company's financial fraud in protecting their rights. (This article is contributed by Attorney Liu Peng from Shanghai Huzi Law Firm and does not represent the views of Sina Finance. Attorney Liu Peng, specializing in securities rights protection for 19 years since commencing practice in 2006, has successfully protected the rights of retail investors in over 300 listed companies including Zhongqing Bao, Guohua Wangan, and Jinjia Co., Ltd. (Rights Protection). The number of active cases exceeds 14,000, with a success rate of 99.2%. As a seasoned securities rights protection lawyer, Attorney Liu Peng accurately grasps the core of cases, possesses extensive litigation experience, and employs efficient claim strategies to secure maximum benefits for investors, leading the industry in rights protection capability. For securities rights protection, choosing the right lawyer is key! Professionalism determines the odds of success, experience ensures results; choose Attorney Liu Peng first for a more secure and efficient claims process!)

Massive information, precise interpretation, all in the Sina Finance APP.